Advertisement

Clinical efficacy and tolerability of new low-level blue and red light therapy technology in the treatment of mild to moderate acne

        Acne vulgaris is a multifactorial skin disease, characterized by proliferation of bacteria, hyperkeratinization, inflammation, and excess sebum production, mainly prevalent in adolescents and young adults. Current over-the-counter treatment options include topical therapies such as benzoyl peroxide (BPO) and salicylic acid, but patient adherence to topical treatments can often be challenging. Various types of blue and red light-emitting diodes (LEDs) have been used independently and in combination as an alternative, chemical-free option for the treatment of acne. Recent research has further elucidated the antibacterial efficacy of blue light (up to 440 nm) through its interaction with the porphyrin produced by Propionbacterium acnes, and research has also demonstrated the significant antiinflammatory activity of red light via modulation of cytokine release and its effect on hyperkeratinization. A 12-week, multicenter, evaluator-blinded clinical study was conducted to evaluate a new low-level blue and red light therapy technology in men and women (12-40 years of age) with mild to moderate acne. Subjects were randomized at baseline to receive either a once-per-day 10 minute treatment with the combination blue and red light technology, or twice-per-day treatment with topical 2.5% BPO. The light therapy technology provided simultaneous low-level blue and red exposure to the face, in 1-step, with all product treatments able to be performed at home. The primary efficacy variable was the percent change from baseline to week 12 in total lesion counts, with Investigator Global Acne (IGA) assessment, self-assessment questionnaires, and skin tolerance also evaluated throughout the course of the study. The new low-level blue and red light therapy technology was found to be well-tolerated and significantly reduced total acne lesion counts over the 12 week study compared with baseline (P < .05). Subjects also reported significant improvements (P < .05) in their acne and overall skin appearance, which is critical for continued compliance to a daily treatment regimen. Improvement in the BPO group was also observed throughout the course of the clinical study. This clinical study demonstrated the efficacy and tolerance of a new low-level blue and red light therapy technology. This 1-step at-home light therapy now provides an effective, easy-to-use, chemical and UV-free treatment option ideally suited for mild-to-moderate acne patients.
        To read this article in full you will need to make a payment
        AAD Member Login
        AAD Members, full access to the journal is a member benefit. Use your society credentials to access all journal content and features
        Already a print subscriber? Claim online access
        Already an online subscriber? Sign in
        Institutional Access: Sign in to ScienceDirect